ClinicalTrials.gg
RecruitingNCT04710576AGAVE-201Updated Jun 16, 2026Results posted

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

A Phase 2 interventional study of Axatilimab in Chronic Graft-versus-host-disease, sponsored by Syndax Pharmaceuticals. Recruiting at 121 sites in 16 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Syndax Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
296
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome — 5 open to participants now, 9 under way, 3 of them phase 3. axatilimab · Bronchiolitis Obliterans Syndrome.

Planned enrollment
Largest of 10
296 · median 50
Started
2021
the only one that year
Phase 2
5 of 10
4 open now
Registered
2nd of 10
by date
Lead sponsor
2 of 10
Syndax Pharmaceuticals

Among the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome, this one has the largest planned enrollment, is the only one that started in 2021, is one of 5 in phase 2, and was the 2nd registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

5 of the 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About axatilimab

axatilimab: first FDA approval 2024 (NIKTIMVO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing axatilimab in Bronchiolitis Obliterans Syndrome, or all of them as a file.
02

Study summary

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.

Read the detailed description

AGAVE-201 is a Phase 2, open-label, randomized, multicenter study to evaluate the efficacy, safety, and tolerability of axatilimab in participants with recurrent or refractory active cGVHD after failure of at least 2 prior lines of systemic therapy due to progression of disease, intolerability, or toxicity.

Participants will be randomized to receive 1 of 3 different axatilimab treatment regimens in 28-day treatment cycles for up to 2 years.

03

Conditions studied

  • Chronic Graft-versus-host-disease

Keywords

  • cGVHD
  • AGAVE-201
  • GVHD
  • graft versus host disease
  • graft-versus-host-disease
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be 2 years of age or older, at the time of signing the .
  2. Participants who are hematopoietic stem cell transplantation (HSCT) recipients with active cGVHD requiring systemic immune suppression. Active cGVHD is defined as the presence of signs and symptoms of cGVHD per 2014 NIH Consensus Development Project on Criteria for Clinical trials in cGVHD.
  3. Participants with or recurrent active cGVHD despite at least 2 .

    • Refractory disease defined as meeting any of the following criteria:

      • The development of 1 or more new sites of disease while being treated for cGVHD.
      • Progression of existing sites of disease despite at least 1 month of standard or investigation therapy for cGVHD.
      • Participants who have not achieved a response within 3 months on their prior therapy for cGVHD and for whom the treating physician believes a new systemic therapy is required.
    • Recurrent cGVHD is active, symptomatic disease (after an initial response to prior therapy) as defined, based on the NIH 2014 consensus criteria, by organ-specific or global assessment or for which the physician believes that a new line of systemic therapy is required.
  4. Participants may have persistent, active acute and cGVHD manifestations (overlap syndrome), as defined by 2014 NIH Consensus Development Project on Criteria for Clinical trials in cGVHD.
  5. Performance Scale of ≥60 (if aged 16 years or older); Lansky Performance Score of ≥60 (if aged \<16 years)
  6. Adequate organ and bone marrow functions evaluated during the 14 days prior to randomization.
  7. (CrCl) ≥30 milliliter/minute based on the Cockcroft-Gault formula in adult participants and Schwartz formula in pediatric participants.
  8. use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  9. Concomitant use a of systemic is allowed but not required. Topical and inhaled corticosteroid agents are allowed. If a participant is taking corticosteroids at study randomization, they must be on a stable dose of corticosteroids for at least 2 weeks prior to Cycle 1 Day 1.
  10. Concomitant use of CNI or mammalian target of repamycin (mTOR) inhibitors (sirolimus or everolimus) is allowed but not required.
  11. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and protocol. A parent/guardian should provide consent for pediatric participants unable to provide consent themselves; in addition, where applicable pediatric participants should sign their own assent form.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Has acute without manifestations of cGVHD.
  2. Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.
  3. History of acute or chronic pancreatitis.
  4. History of myositis.
  5. History or other evidence of severe illness, uncontrolled infection or any other conditions that would make the participant, in the opinion of the Investigator, unsuitable for the study.
  6. Participants with acquired immune deficiency syndrome (AIDS).
  7. (defined as hepatitis B virus [HBV] surface antigen positive and HBV core antibody positive, with positive HBV deoxyribonucleic acid [DNA], or HBV positive core antibody alone with positive HBV DNA. (defined as positive hepatitis C [HCV] antibody with positive HCV ribonucleic acid [RNA]).
  8. Diagnosed with another (other than malignancy for which transplant was performed) within 3 years of randomization, unless previously treated with curative intent and approved by Sponsor's Medical Monitor (for example, completely resected basal cell or squamous cell carcinoma of the skin, resected in situ cervical malignancy, resected breast ductal carcinoma in situ, or low-risk prostate cancer after curative resection).
  9. Female participant who is pregnant or breastfeeding.
  10. Previous exposure to CSF1-R targeted therapies.
  11. Taking agents for treatment of cGVHD other than or either a CNI or mTOR inhibitor is prohibited.
  12. For approved or commonly used agents, other than corticosteroids, CNI and mTOR inhibitor, a of 2 weeks or 5 half-lives, whichever is shorter, is required at study enrollment.
  13. Receiving another treatment within 28 days of randomization.
  14. Participants should not be participating in any other interventional study. Pediatric participants are encouraged to also participate in the ongoing developmental studies of the Pediatric cGVHD Symptom Scale (PCSS).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
296 participants (estimated)

Study arms

  • Experimental
    Axatilimab Dose Cohort 1

    Participants will be administered axatilimab 0.3 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks for up to 2 years.

    Drug: Axatilimab

  • Experimental
    Axatilimab Dose Cohort 2

    Participants will be administered axatilimab 1 mg/kg IV every 2 weeks for up to 2 years.

    Drug: Axatilimab

  • Experimental
    Axatilimab Dose Cohort 3

    Participants will be administered axatilimab 3 mg/kg IV every 4 weeks for up to 2 years.

    Drug: Axatilimab

Interventions

  • Axatilimab is a high-affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor-derived macrophages that mediate the disease processes involved in cGVHD.

    Also known as: Niktimvo, SNDX-6352

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) in the First 6 Cycles as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease (cGVHD)

    The ORR was defined as the percentage of participants with objective response (complete response \[CR\] or partial response \[PR\]). CR was defined as resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site.

    Time frame: First 6 cycles (up to Cycle 7 Day 1; each cycle = 4 weeks)

Secondary outcomes

  1. ORR on Study as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD

    Time frame: Up to 2 years

  2. Number of Participants With a Clinically Significant Improvement in Normalized Score on the Modified Lee Symptom Scale

    Time frame: Up to 2 years

  3. Duration of Response

    Duration of response is defined as the time from initial partial response or complete response until documented progression of cGVHD, start of new therapy, or death for any reason.

    Time frame: Up to 2 years

  4. Sustained Response Rate

    Sustained response rate is defined as the number of participants with objective response lasting for at least 20 weeks (140 days) from the time of initial response. Responses will be assessed based on the 2014 NIH Consensus Development Project on Clinical Trials in cGVHD.

    Time frame: Up to 2 years

  5. Organ-specific Response Rate

    Organ-specific response is defined as the number of participants with objective response for the nine individual organs based on 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD (skin, eyes, mouth, esophagus, upper gastrointestinal \[GI\], lower GI, liver, lungs and joints and fascia).

    Time frame: Up to 2 years

  6. Joints and Fascia Response Rate Based on Refined NIH Response Algorithm for cGVHD

    Time frame: Up to 2 years

  7. Percent Reductions in Average Daily Doses (or Equivalent) of Corticosteroid

    Time frame: Up to 2 years

  8. Number of Participants Who Discontinue Corticosteroid Use

    Time frame: Up to 2 years

  9. Percent Reductions in Average Daily Doses (or Equivalent) of Calcineurin Inhibitors (CNI)

    Time frame: Up to 2 years

  10. Number of Participants Who Discontinue CNIs

    Time frame: Up to 2 years

  11. Change From Baseline in Circulating Monocyte Number and Phenotype (CD14/16)

    Time frame: Baseline, up to 2 years

  12. Number of Participants With Anti-Drug Antibody

    Time frame: Up to 2 years

  13. Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of Last Measurable Concentration (AUC0-t)

    Time frame: Approximately 12 months

  14. Number of Participants With Treatment-emergent Adverse Events

    Time frame: Up to 2 years

  15. Change From Baseline in Bone Turnover Markers

    Time frame: Baseline, up to 2 years

  16. Change From Baseline in Bone Density

    Time frame: Baseline, up to 2 years

  17. Change From Baseline in Colony Stimulating Factor 1 (CSF-1) and Interleukin 34 (IL-34) Levels

    Time frame: Baseline, up to 2 years

07

Results

Posted Oct 10, 2024

Participant flow

Data collection for the primary outcome measure is complete for all participants and new participants are only being recruited for secondary outcome measures. That is, the primary outcome measure reported will not be revised and additional primary outcome measures will not be added.

Participant flow — Overall Study
MilestoneAxatilimab 0.3 mg/kg Q2WAxatilimab 1 mg/kg Q2WAxatilimab 3 mg/kg Q4W
Started808180
Received at least 1 dose of study drug798179
Completed011
Not completed808079
Withdrew: Participants still in the study737060
Withdrew: Death2712
Withdrew: Withdrawal by subject437
Withdrew: Sponsor decision100

Outcome measures

PrimaryOverall Response Rate (ORR) in the First 6 Cycles as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease (cGVHD)

The ORR was defined as the percentage of participants with objective response (complete response \[CR\] or partial response \[PR\]). CR was defined as resolution of all manifestations in each organ or site, and PR was defined as improvement in at least 1 organ or site without progression in any other organ or site.

Time frame:
First 6 cycles (up to Cycle 7 Day 1; each cycle = 4 weeks)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) in the First 6 Cycles as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease (cGVHD)
percentage of participantsAxatilimab 0.3 mg/kg Q2WAxatilimab 1 mg/kg Q2WAxatilimab 3 mg/kg Q4W
Overall Response Rate (ORR) in the First 6 Cycles as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease (cGVHD)73.8 (62.7 to 83.0)66.7 (55.3 to 76.8)50.0 (38.6 to 61.4)
SecondaryORR on Study as Defined by the 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD
Time frame:
Up to 2 years

Results for this outcome have not been posted.

SecondaryNumber of Participants With a Clinically Significant Improvement in Normalized Score on the Modified Lee Symptom Scale
Time frame:
Up to 2 years

Results for this outcome have not been posted.

SecondaryDuration of Response

Duration of response is defined as the time from initial partial response or complete response until documented progression of cGVHD, start of new therapy, or death for any reason.

Time frame:
Up to 2 years

Results for this outcome have not been posted.

SecondarySustained Response Rate

Sustained response rate is defined as the number of participants with objective response lasting for at least 20 weeks (140 days) from the time of initial response. Responses will be assessed based on the 2014 NIH Consensus Development Project on Clinical Trials in cGVHD.

Time frame:
Up to 2 years

Results for this outcome have not been posted.

SecondaryOrgan-specific Response Rate

Organ-specific response is defined as the number of participants with objective response for the nine individual organs based on 2014 NIH Consensus Development Project on Criteria for Clinical Trials in cGVHD (skin, eyes, mouth, esophagus, upper gastrointestinal \[GI\], lower GI, liver, lungs and joints and fascia).

Time frame:
Up to 2 years

Results for this outcome have not been posted.

SecondaryJoints and Fascia Response Rate Based on Refined NIH Response Algorithm for cGVHD
Time frame:
Up to 2 years

Results for this outcome have not been posted.

SecondaryPercent Reductions in Average Daily Doses (or Equivalent) of Corticosteroid
Time frame:
Up to 2 years

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Discontinue Corticosteroid Use
Time frame:
Up to 2 years

Results for this outcome have not been posted.

SecondaryPercent Reductions in Average Daily Doses (or Equivalent) of Calcineurin Inhibitors (CNI)
Time frame:
Up to 2 years

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Discontinue CNIs
Time frame:
Up to 2 years

Results for this outcome have not been posted.

SecondaryChange From Baseline in Circulating Monocyte Number and Phenotype (CD14/16)
Time frame:
Baseline, up to 2 years

Results for this outcome have not been posted.

SecondaryNumber of Participants With Anti-Drug Antibody
Time frame:
Up to 2 years

Results for this outcome have not been posted.

SecondaryArea Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of Last Measurable Concentration (AUC0-t)
Time frame:
Approximately 12 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment-emergent Adverse Events
Time frame:
Up to 2 years

Results for this outcome have not been posted.

SecondaryChange From Baseline in Bone Turnover Markers
Time frame:
Baseline, up to 2 years

Results for this outcome have not been posted.

SecondaryChange From Baseline in Bone Density
Time frame:
Baseline, up to 2 years

Results for this outcome have not been posted.

SecondaryChange From Baseline in Colony Stimulating Factor 1 (CSF-1) and Interleukin 34 (IL-34) Levels
Time frame:
Baseline, up to 2 years

Results for this outcome have not been posted.

Adverse events

Collected over From first dose of study drug up to 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axatilimab 0.3 mg/kg Q2W2/80 (2.5%)30/79 (38%)74/79 (93.7%)
Axatilimab 1 mg/kg Q2W7/81 (8.6%)33/81 (40.7%)78/81 (96.3%)
Axatilimab 3 mg/kg Q4W12/80 (15%)38/79 (48.1%)78/79 (98.7%)
Most frequent serious events
Showing 10 of 138
Most frequent serious events
EventAxatilimab 0.3 mg/kg Q2WAxatilimab 1 mg/kg Q2WAxatilimab 3 mg/kg Q4W
PneumoniaInfections and infestations7/798/814/79
COVID-19Infections and infestations2/794/815/79
CellulitisInfections and infestations0/793/813/79
Respiratory failureRespiratory, thoracic and mediastinal disorders3/792/813/79
HypoxiaRespiratory, thoracic and mediastinal disorders0/793/810/79
Generalised oedemaGeneral disorders0/790/812/79
COVID-19 pneumoniaInfections and infestations0/791/812/79
GastroenteritisInfections and infestations0/790/812/79
InfluenzaInfections and infestations2/792/810/79
Parainfluenzae virus infectionInfections and infestations2/790/810/79
Most frequent other events
Showing 10 of 72
Most frequent other events
EventAxatilimab 0.3 mg/kg Q2WAxatilimab 1 mg/kg Q2WAxatilimab 3 mg/kg Q4W
Blood creatine phosphokinase increasedInvestigations9/7926/8149/79
Aspartate aminotransferase increasedInvestigations11/7931/8143/79
Lipase increasedInvestigations9/7921/8139/79
Amylase increasedInvestigations3/7910/8134/79
Blood lactate dehydrogenase increasedInvestigations11/7922/8132/79
Alanine aminotransferase increasedInvestigations10/7918/8131/79
Periorbital oedemaEye disorders2/7919/8123/79
FatigueGeneral disorders18/7916/8121/79
Gamma-glutamyltransferase increasedInvestigations8/7916/8121/79
DiarrhoeaGastrointestinal disorders13/7918/817/79

Baseline characteristics

The intent-to-treat (ITT) analysis set for each dose level included all participants randomized to the dose level.

Age, Continuous
Age, Continuous(years)Axatilimab 0.3 mg/kg Q2WAxatilimab 1 mg/kg Q2WAxatilimab 3 mg/kg Q4WTotal
Mean49.4 ± 16.8854.0 ± 12.6550.8 ± 16.0251.4 ± 15.34
Sex: Female, Male
Sex: Female, Male(Participants)Axatilimab 0.3 mg/kg Q2WAxatilimab 1 mg/kg Q2WAxatilimab 3 mg/kg Q4WTotal
Female33302790
Male475153151
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Axatilimab 0.3 mg/kg Q2WAxatilimab 1 mg/kg Q2WAxatilimab 3 mg/kg Q4WTotal
Hispanic or Latino59519
Not Hispanic or Latino736973215
Unknown or Not Reported2327
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Axatilimab 0.3 mg/kg Q2WAxatilimab 1 mg/kg Q2WAxatilimab 3 mg/kg Q4WTotal
American Indian or Alaska Native0101
Asian44816
Native Hawaiian or Other Pacific Islander0011
Black or African American2215
White687062200
More than one race0000
Unknown or Not Reported64818
08

Study locations

13 of 121 sites recruiting
  • University of Alabama at Birmingham - Children's of Alabama
    Birmingham, Alabama 35233, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
    Recruiting
  • City of Hope
    Duarte, California 91010, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Southern California Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    Recruiting
  • University of California, Los Angeles (UCLA) - Medical Center
    Los Angeles, California 90059, United States
    Completed

    Not enrolling at this site — choose another above.

  • Stanford Cancer Center
    Stanford, California 94305, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Children's National Medical Center
    Washington D.C., District of Columbia 20010, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Florida (UF)
    Gainesville, Florida 32610, United States
    Completed

    Not enrolling at this site — choose another above.

  • Mayo Clinic - Jacksonville
    Jacksonville, Florida 32224, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Miami
    Miami, Florida 33136, United States
    Recruiting
  • AdventHealth Orlando
    Orlando, Florida 32806, United States
    Completed

    Not enrolling at this site — choose another above.

  • Moffitt
    Tampa, Florida 33612, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Emory University
    Atlanta, Georgia 30322, United States
    Recruiting
  • Northside Hospital
    Atlanta, Georgia 30342, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The University of Chicago Medical Center (UCMC)
    Chicago, Illinois 60637, United States
    Recruiting
  • Indiana University Health Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Franciscan Health Indianapolis
    Indianapolis, Indiana 46237, United States
    Completed

    Not enrolling at this site — choose another above.

  • Tulane University Medical Center
    New Orleans, Louisiana 70112, United States
    Completed

    Not enrolling at this site — choose another above.

  • Johns Hopkins Kimmel Cancer Center
    Baltimore, Maryland 21231-2410, United States
    Completed

    Not enrolling at this site — choose another above.

  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Massachusetts Memorial Medical Center
    Worcester, Massachusetts 01655, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Michigan
    Ann Arbor, Michigan 48084, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
    Recruiting
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
    Completed

    Not enrolling at this site — choose another above.

  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Weill Medical College of Cornell University
    New York, New York 10022, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Stony Brook University Medical Center
    Stony Brook, New York 11794, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Wake Forest
    Winston-Salem, North Carolina 27157, United States
    Completed

    Not enrolling at this site — choose another above.

  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
    Completed

    Not enrolling at this site — choose another above.

  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Completed

    Not enrolling at this site — choose another above.

  • The Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
    Recruiting
  • The Cleveland Clinic Foundation
    Lyndhurst, Ohio 44195, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Oklahoma - Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Oregon Health & Science University
    Portland, Oregon 97239, United States
    Recruiting
  • University of Pittsburgh Medical Center - Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Intermountain Healthcare
    Salt Lake City, Utah 84111, United States
    Recruiting
  • University of Utah
    Salt Lake City, Utah 84112, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Virginia Medical Center
    Charlottesville, Virginia 22908, United States
    Completed

    Not enrolling at this site — choose another above.

  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
    Recruiting
  • University of Wisconsin - Carbone Cancer Center
    Madison, Wisconsin 53792, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Froedtert Hospital and the Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Royal Children's Hospital
    Parkville, Victoria 3052, Australia
    Completed

    Not enrolling at this site — choose another above.

  • Westmead Hospital
    Westmead, Australia
    Completed

    Not enrolling at this site — choose another above.

  • Universitaire Ziekenhuizen Leuven
    Leuven, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • AZ Delta
    Roeselare, Belgium
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Vancouver Coastal Health Authority
    Vancouver, British Columbia V5Z 1M9, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Princess Margaret Hospital
    Toronto, Ontario, Canada
    Completed

    Not enrolling at this site — choose another above.

  • McGill University Health Center - Research Institute
    Montreal, Quebec H3G 1A4, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU Sainte-Justine
    Montreal, Quebec H3T 1C5, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU de Grenoble
    La Tronche, Auvergne-Rhône-Alpes 38700, France
    Completed

    Not enrolling at this site — choose another above.

  • Institut de cancérologie Strasbourg Europe (ICANS)
    Strasbourg, Grand Est 67200, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • IUCT-Oncopole
    Toulouse, Haure-Garrone 31100, France
    Completed

    Not enrolling at this site — choose another above.

  • CHU Amiens Picardie - Hopital Sud
    Amiens, Hauts-de-France 80054, France
    Completed

    Not enrolling at this site — choose another above.

  • CHRU de Lille - Hopital Claude Huriez
    Lille, Hauts-de-France 59037, France
    Completed

    Not enrolling at this site — choose another above.

  • CHRU de Nancy - Hôpitaux de Brabois
    Nancy, France
    Completed

    Not enrolling at this site — choose another above.

  • CHU de Nantes - Hôtel-Dieu
    Nantes, France
    Completed

    Not enrolling at this site — choose another above.

  • Hopital Saint Louis
    Paris, 75010, France
    Completed

    Not enrolling at this site — choose another above.

  • Hopital Pitie Salpetriere
    Paris, 75013, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU Bordeaux - Hopital Haut-Leveque - Centre François Magendie
    Pessac, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • HCL Centre Hospitalier Lyon Sud
    Pierre-Bénite, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitaetsklinikum Carl Gustav Carus Dresden
    Dresden, 01307, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Universitaetsklinikum Jena
    Jena, 07740, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Universitaetsklinikum Leipzig
    Leipzig, 04103, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz
    Mainz, 55131, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Universitaetsklinikum Muenster
    Münster, 48149, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitatsklinikum Regensburg
    Regensburg, 93053, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • General Hospital of Thessaloniki G. Papanikolaou - Hematology Department, BMT Unit
    Eksochi, Thessaloniki 57010, Greece
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Hospital of West Attica - Attikon - Hematology Division
    Athens, Greece
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University General Hospital of Patras
    Pátrai, 26500, Greece
    Completed

    Not enrolling at this site — choose another above.

  • Rambam Health Care Campus
    Haifa, 3109601, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hadassah Medical Center Ein Karem
    Jerusalem, 9112001, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Chaim Sheba Medical Center
    Ramat Gan, 5262160, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • ASST degli Spedali Civili di Brescia
    Brescia, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano
    Milan, 20122, Italy
    Completed

    Not enrolling at this site — choose another above.

  • IRCCS Ospedale San Raffaele
    Milan, 20132, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • ASST di Monza-Ospedale San Gerardo
    Monza, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Fondazione Monza e Brianza per il Bambino e la sua Mamma
    Monza, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Fondazione IRCCS Policlinico San Matteo
    Pavia, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Fondazione Policlinica Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
    Roma, 168, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • AOU Citta della Salute e della Scienza di Torino - Ospedale Regina Margherita
    Torino, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Citta della Salute e della Scienza di Torino - Ospedale le Molinette
    Torino, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach - Klinika Transplantacji Szpiku i Onkohematologii
    Gliwice, 44-102, Poland
    Completed

    Not enrolling at this site — choose another above.

  • Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E. (IPO-Lisboa)
    Lisbon, 1099-023, Portugal
    Completed

    Not enrolling at this site — choose another above.

  • Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE
    Porto, Portugal
    Completed

    Not enrolling at this site — choose another above.

  • National University Hospital
    Singapore, 119074, Singapore
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • KK Women's and Children hospital
    Singapore, 229899, Singapore
    Completed

    Not enrolling at this site — choose another above.

  • Singapore General Hospital
    Singapore, Singapore
    Completed

    Not enrolling at this site — choose another above.

  • Pusan National University Hospital
    Busan, South Korea
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Korea University Anam Hospital
    Seoul, South Korea
    Completed

    Not enrolling at this site — choose another above.

  • Seoul National University Hospital
    Seoul, South Korea
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Severance Hospital
    Seoul, South Korea
    Completed

    Not enrolling at this site — choose another above.

  • Hospital Universitario Virgen del Rocio
    Seville, Seville 41013, Spain
    Active, not recruiting

    Not enrolling at this site — choose another above.

Showing the first 100 of 121 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Yang YO, Sokolov V, Volkova A, Liu X, Leon C, Kosinsky Y, Barker B, Zhang X, Ordentlich P, Sheng J, Chen X. Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft-Versus-Host Disease. Clin Pharmacol Ther. 2025 Mar;117(3):704-715. doi: 10.1002/cpt.3503. Epub 2024 Dec 20. PubMed 39704205 ↗
  • Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, Hamadani M, Arai S, Salhotra A, Perez-Simon JA, Alousi A, Choe H, Kwon M, Bermudez A, Kim I, Socie G, Chhabra S, Radojcic V, O'Toole T, Tian C, Ordentlich P, DeFilipp Z, Kitko CL; AGAVE-201 Investigators. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2024 Sep 19;391(11):1002-1014. doi: 10.1056/NEJMoa2401537. PubMed 39292927 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Apr 2023, 25 months.

Results were first posted in Oct 2024, 1 year 6 months after primary completion. A results delay was requested in Jun 2024.

Of 63 phase 2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2021
First posted
Jan 14, 2021
StartActual
Mar 4, 2021
Primary completionActual
Apr 7, 2023
CompletionEst.
Sep 2027
Results delay requested
Jun 13, 2024
Results first posted
Oct 10, 2024
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04710576
Responsible party
Sponsor
First posted
Jan 14, 2021
Start date
Mar 4, 2021
Primary completion
Apr 7, 2023
Completion
Sep 2027 (estimated)
Results posted
Oct 10, 2024
Last update
Jun 16, 2026

Study contacts

Syndax Pharmaceuticals
Contact
clinicaltrials@syndax.com
781-419-1400
Ellen Hooper, M.D.
study director · Syndax Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axatilimab

Start the discussion